CTLA-4 Control over Foxp3 + Regulatory T Cell Function
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Naturally occurring Foxp3+CD4+ regulatory T cells (Tregs) are essential for maintaining immunological self-tolerance and immune homeostasis. Here, we show that a specific deficiency of cytotoxic T lymphocyte antigen 4 (CTLA-4) in Tregs results in spontaneous development of systemic lymphoproliferation, fatal T cell-mediated autoimmune disease, and hyperproduction of immunoglobulin E in mice, and it also produces potent tumor immunity. Treg-specific CTLA-4 deficiency impairs in vivo and in vitro suppressive function of Tregs-in particular, Treg-mediated down-regulation of CD80 and CD86 expression on dendritic cells. Thus, natural Tregs may critically require CTLA-4 to suppress immune responses by affecting the potency of antigen-presenting cells to activate other T cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The central role that CTLA-4 plays in immunological tolerance is exemplified by experiments in mice that lack the CTLA-4 gene globally or specifically in the Forkhead box P3 (FoxP3)+ Treg compartment. These animals develop lymphoproliferative disorders and die at a young age (25, 26).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Indeed, this process is an important mechanism by which Tregs mediate immune suppression on bystander cells (25).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Of note, although CTLA4 blockade was shown to cause selective depletion of intratumoral Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) in murine models and ex vivo experiments on human tumor samples (24)(25)(26),”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [24]
In the citing paper
“The CTLA-4 regulatory effects mainly temper the activation of CD4+ helper T cells while boosting regulatory T cells (Tregs) (Doyle et al., 2001; Wing et al., 2008), leading to a pro-tumor immunosuppressive phenotype.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Wing et al., 2008
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Self-citationRegulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Self-citationRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Research works printed but not linked: 1
- 10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x · doi:10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x
Cited by
Items 301–400 of 1,010
Wang, L., de Zoeten, E. F., Greene, M. I., & Hancock, W. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3031 · Cited by 186
Zhu, Q., Egelston, C., Gagnon, S., Sui, Y., Belyakov, I. M., Klinman, D. M., & Berzofsky, J. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39293 · Cited by 186
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185
“CTLA4 is one of the most important immune-suppressive molecules of T reg cells 101–103 .”
BackgroundCell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation
Wing, K., Yamaguchi, T., & Sakaguchi, S. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.06.002 · Cited by 183
Self-citationRegulatory T Cells as Immunotherapy
Singer, B. D., King, L. S., & D’Alessio, F. R. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00046 · Cited by 183
“Polymorphisms of cytotoxic T-lymphocyte antigen 4 (CTLA-4) – a co-signaling molecule with vital importance to Treg function (10) – are also linked to autoimmunity (11).”
BackgroundKato, H., & Perl, A. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40380 · Cited by 182
“These findings are consistent with the notion that CTLA-4–dependent down-regulation of CD80/CD86 on APCs is critical for the suppressor function of Treg cells (39).”
BackgroundResultKumagai, S., Itahashi, K., & Nishikawa, H. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00870-6 · Cited by 187
Hu, R., Lin, H., Wang, M., Zhao, Y., Liu, H., Min, Y., Yang, X., Gao, Y., & Yang, M. (2021) · Journal of Animal Science and Biotechnology · doi:10.1186/s40104-020-00532-4 · Cited by 181
“Mammalian Foxp3+ Tregs can exert the immunosuppressive effect on effective T cells by increasing the gene expression of CTLA-4 [60].”
BackgroundInfluentialCAF-induced physical constraints controlling T cell state and localization in solid tumours
Arpinati, L., Carradori, G., & Scherz‐Shouval, R. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00740-4 · Cited by 183
“201,205,206), ultimately hindering effector CD8 + T cell activity and proliferation and contributing to impaired antitumour immunity.”
Human FoxP3+CD4+ regulatory T cells: their knowns and unknowns
Miyara, M., & Sakaguchi, S. (2011) · Immunology & Cell Biology · doi:10.1038/icb.2010.137 · Cited by 180
“13 CTLA-4 is essential for Treg function as shown by FoxPp Treg-specific deficiency of the CTLA-4 gene, which produces severe autoimmunesinflammatory diseases similar to those induced by FoxP3 mutation or deficiency”
BackgroundSelf-citationRowe, J. H., Ertelt, J. M., Aguilera, M. N., Farrar, M. A., & Way, S. S. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.06.005 · Cited by 179
“We focused initially on CTLA-4 and IL-10 because each play dominant roles for Treg suppression in other in vivo contexts (Asseman et al., 1999; Belkaid et al., 2002; Friedline et al., 2009; Rubtsov et al., 2008; Wing et al., 2008).”
BackgroundInfluentialWang, C. J., Heuts, F., Ovcinnikovs, V., Wardzinski, L., Bowers, C., Schmidt, E. M., Kogimtzis, A., Kenefeck, R., Sansom, D. M., & Walker, L. S. K. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414576112 · Cited by 179
“S5A), consistent with the previous demonstration that deficiency of CTLA-4 in Treg triggers the production of antiparietal cell antibodies (Abs) and autoimmune gastritis (9).”
BackgroundInfluentialKabacaoglu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 179
“Overall, CTLA-4 engagement downregulates effector T cell activity, while enhancing Treg immunosuppressive activity (59, 62).”
BackgroundInduced and Natural Regulatory T Cells in the Development of Inflammatory Bowel Disease
Mayne, C. G., & Williams, C. B. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318281f5a3 · Cited by 178
Driver, J. P., Serreze, D. V., & Chen, Y.-G. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-010-0204-1 · Cited by 178
“CTLA-4 plays an important role in downregulating effector T-cell responses and maintaining Treg function [35, 36], In NOD mice, it was found that T1D susceptibility correlates with low levels of a novel Ctla-4 splice variant referred to as ligand-independent CTLA4 (liCTLA-4) due to a single nucleotide polymorphism in…”
BackgroundInducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
Sanmamed, M. F., & Chen, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000061 · Cited by 178
“It has been shown that CTLA-4 expression on Treg cells is critical for its expansion and activity.(15) Anti– CTLA-4 treatment increases T effector/Treg cells ratio selectively in tumor site, but in mice lacking FcγRIVanti–CTLA-4 treatment fails to elicit tumor protection.”
BackgroundImmunotherapy advances for glioblastoma
Reardon, D. A., Freeman, G., Wu, C., Chiocca, E. A., Wucherpfennig, K. W., Wen, P. Y., Fritsch, E. F., Curry, W. T., Sampson, J. H., & Dranoff, G. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou212 · Cited by 178
“CTLA-4 can also suppress immune reactivity by decreasing helper T-cell activity and augmenting myeloid-derived suppressor cells as well as regulatory T cells, in which CTLA-4 is constitutively expressed.(177) – 179 The critical modulatory suppression of immune activation by CTLA-4 is underscored by lethal autoimmunity…”
BackgroundDendritic Cells As Inducers of Peripheral Tolerance
Iberg, C. A., Jones, A., & Hawiger, D. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.07.007 · Cited by 178
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
Buchbinder, E., & Hodi, F. S. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80012 · Cited by 178
“As noted above, CTLA-4–blocking antibodies increase CD8 + lymphocytes and deplete Tregs.”
BackgroundInfluentialThe Role of Antigen Spreading in the Efficacy of Immunotherapies
Brossart, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0305 · Cited by 180
What did we learn from CTLA‐4 insufficiency on the human immune system?
Mitsuiki, N., Schwab, C., & Grimbacher, B. (2019) · Immunological Reviews · doi:10.1111/imr.12721 · Cited by 177
Yang, Z., Zhang, B., Li, D., Lv, M., Huang, C., Shen, G.-X., & Huang, B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008922 · Cited by 177
“The means by which Treg cells suppress tumor-specific T cells includes 1) secretion of suppressor cytokines IL-10 and TGF-b [11]; 2) suppression of the function of APC through CTLA4 pathway [12]; 3) hydrolysis of extracellular ATP”
BackgroundCritical role of the gut microbiota in immune responses and cancer immunotherapy
Li, Z., Xiong, W., Liang, Z., Wang, J., Zeng, Z., Kołat, D., Li, X., Zhou, D., Xu, X., & Zhao, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01541-w · Cited by 176
“CTLA-4 is a major negative receptor of T cells and has upregulated expression upon T-cell activation [220–226].”
BackgroundMorikawa, H., & Sakaguchi, S. (2014) · Immunological Reviews · doi:10.1111/imr.12174 · Cited by 176
“We have previously shown that Treg cell-specific CTLA-4 deficiency abolishes in vivo and in vitro Treg suppressive activity, producing fatal autoimmune and inflammatory diseases in otherwise normal mice (58).”
BackgroundSelf-citationPD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
Asano, T., Meguri, Y., Yoshioka, T., Kishi, Y., Iwamoto, M., Nakamura, M., Sando, Y., Yagita, H., Koreth, J., Kim, H. T., et al. (2017) · Blood · doi:10.1182/blood-2016-09-741629 · Cited by 176
Lymph node – an organ for T‐cell activation and pathogen defense
Gasteiger, G., Ataide, M. A., & Kastenmüller, W. (2016) · Immunological Reviews · doi:10.1111/imr.12399 · Cited by 177
“Treg have also been proposed to remove these costimulatory molecules through a process called transendocytosis (189, 190).”
BackgroundDevelopment of immune checkpoint therapy for cancer
Fritz, J. M., & Lenardo, M. J. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 175
“T reg cells constitutively express high surface CTLA-4, making them potent antagonists of T cell activation (Read et al., 2000; Wing et al., 2008; Qureshi et al., 2011; Hou et al., 2015).”
BackgroundResultThe link between circulating follicular helper T cells and autoimmunity
Walker, L. S. K. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00693-5 · Cited by 174
Chen, X., Song, X., Li, K., & Zhang, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00292 · Cited by 174
“Using human FcγR-transgenic mice, Arce Vargas et al. clearly demonstrated that antibodies with isotypes equivalent to ipilimumab increased the CD8+ to Treg ratio by depleting intra-tumoral Tregs to promote tumor rejection (15).”
BackgroundInfluentialSingle dose of anti–CTLA-4 enhances CD8 + T-cell memory formation, function, and maintenance
Pedicord, V. A., Montalvo, W., Leiner, I. M., & Allison, J. P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016791108 · Cited by 174
“Because both CTLA4 blockade and cell-intrinsic CTLA-4 deficiency have been shown to decrease the suppressive function of CD4 Tregs (18, 25, 26), it also possible that the increased expansion and function of memory CD8 T cells apparent in mice treated with CTLA-4 blockade is due to decreased CD4 Treg-mediated suppressi…”
BackgroundMelnik, B. C., John, S., & Schmitz, G. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-43 · Cited by 174
“CTLA-4 has been shown in mice to control Foxp3+ regulatory T cell function [121].”
BackgroundYang, L., & Lin, P. C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.001 · Cited by 155
“Drugs targeting CTLA4 unleashes anti-tumor immunity [25, 29].”
Joller, N., & Kuchroo, V. K. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_62 · Cited by 133
“In addition to regulating effector T cell responses directly, co-inhibitory receptors like CTL-4 also dampen T cells responses indirectly by promoting the suppressive function of regulatory T cells (Tregs) (Wing et al. 2008).”
BackgroundYamagishi, R., Kamachi, F., Nakamura, M., Yamazaki, S., Kamiya, T., Takasugi, M., Cheng, Y., Nonaka, Y., Yukawa-Muto, Y., Thuy, L. T. T., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl7209 · Cited by 173
Naturally occurring regulatory T cells: markers, mechanisms, and manipulation
Schmetterer, K. G., Neunkirchner, A., & Pickl, W. F. (2012) · The FASEB Journal · doi:10.1096/fj.11-193672 · Cited by 173
“Similarly, conditional knockout of CTLA-4 in murine nTregs severely impairs their suppressive capacity, resulting in autoimmune pathology with splenomegaly, lymphadenopathy, autoimmune gastritis and 1000fold increased IgE levels (92).”
BackgroundThe Family of IL-10-Secreting CD4+ T Cells
(2010) · Advances in Immunology · doi:10.1016/s0065-2776(10)05004-2 · Cited by 172
Granito, A., Muratori, L., Lalanne, C., Quarneti, C., Ferri, S., Guidi, M., Lenzi, M., & Muratori, P. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i22.2994 · Cited by 172
McGary, C. S., Deleage, C., Harper, J., Micci, L., Ribeiro, S. P., Paganini, S., Kuri-Cervantes, L., Benne, C., Ryan, E. S., Balderas, R., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.018 · Cited by 156
“CTLA-4PD-1 CD4 T Cells Include a High Frequency of Regulatory T Cells CTLA-4 is one of the markers that defines regulatory T (Treg) cells (Read et al., 2000;Wing et al., 2008); hence, we investigated in ex vivo conditions the overlap between the above defined CTLA-4PD-1 T cells and CTLA-4 Treg cells (Figure 2A).”
BackgroundSTAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer
Oweida, A. J., Darragh, L., Phan, A., Binder, D., Bhatia, S., Mueller, A., Court, B. V., Milner, D., Raben, D., Woessner, R., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz036 · Cited by 156
“antibody, which has been shown to deplete Tregs (20), or antiCTLA4, which has been shown to block the inhibitory activity of Tregs (21).”
BackgroundICOS+ Tregs: A Functional Subset of Tregs in Immune Diseases
Li, D.-Y., & Xiong, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02104 · Cited by 172
“have also demonstrated that CTLA-4 mainly affects Treg suppressive function in the periphery, the generation of FOXP3 thymocytes is minimally altered in CTLA-4 conditional knockout mice (87).”
BackgroundIse, W., Kohyama, M., Nutsch, K. M., Lee, H. M., Suri, A., Unanue, E. R., Murphy, T. L., & Murphy, K. M. (2010) · Nature Immunology · doi:10.1038/ni.1835 · Cited by 171
“, it seems to be essential for T reg cell function in vivo , as T reg cell–specific deletion of CTLA-4 causes spontaneous development of systemic lymphoproliferation and fatal disease in mic”
BackgroundMechanisms underlying immunosuppression by regulatory cells
Goldmann, O., Nwofor, O. V., Chen, Q., & Medina, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328193 · Cited by 174
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
Guereschi, M. G., Araujo, L. P., Maricato, J. T., Takenaka, M. C., Nascimento, V. M., Vivanco, B. C., Reis, V. O., Keller, A. C., Brum, P. C., & Basso, A. S. (2013) · European Journal of Immunology · doi:10.1002/eji.201243005 · Cited by 170
Immune suppression and reversal of the suppressive tumor microenvironment
Shimizu, K., Iyoda, T., Okada, M., Yamasaki, S., & Fujii, S.-I. (2018) · International Immunology · doi:10.1093/intimm/dxy042 · Cited by 157
Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
Marhelava, K., Pilch, Z., Bajor, M., Graczyk‐Jarzynka, A., & Zagożdżon, R. (2019) · Cancers · doi:10.3390/cancers11111756 · Cited by 170
“It is known that high levels of CTLA-4 correlate with reduced activati n of T cells primarily in lymph nodes, but also in peripheral tissues and that CTLA-4 expression on T regulatory cells ( regs) has been shown to be crucial for sy temic tol anc [12].”
BackgroundPoirier, N., Azimzadeh, A. M., Zhang, T., Dilek, N., Mary, C., Nguyen, B., Tillou, X., Wu, G., Reneaudin, K., Hervouet, J., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000116 · Cited by 169
Treg(s) in Cancer: Friends or Foe?
Wolf, D., Sopper, S., Pircher, A., Gastl, G., & Wolf, A. M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25016 · Cited by 151
CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
Brunner-Weinzierl, M. C., & Rudd, C. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02737 · Cited by 153
“(1) (5, 43), (2) (28–30, 74), (3) (49), (4) (35, 45), (5) (3, 4, 32), (6)”
BackgroundTargets for immunotherapy of liver cancer
Greten, T. F., & Sangro, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.007 · Cited by 168
“Hence, CTLA-4 is also required for Treg to exert its suppressive activity on activated T cells [8].”
T follicular helper cells and T follicular regulatory cells in rheumatic diseases
Deng, J., Wei, Y., Fonseca, V. R., Graca, L., & Yu, D. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0254-2 · Cited by 168
The interplay of effector and regulatory T cells in cancer
Roychoudhuri, R., Eil, R. L., & Restifo, N. P. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.003 · Cited by 169
“These have been extensively reviewed elsewhere [71] and include CTLA-4-mediated sequestration of CD80 and CD86 on the surface of APC by trogocytosis [74] and expression of inhibitory cytokines such as TGF-b [75– 77], IL-10 [78,79] and IL-35 [80,81].”
BackgroundShafiani, S., Dinh, C., Ertelt, J. M., Moguche, A. O., Siddiqui, I., Smigiel, K. S., Sharma, P., Campbell, D. J., Way, S. S., & Urdahl, K. B. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.003 · Cited by 148
Foxp3+ T Regulatory Cells: Still Many Unanswered Questions—A Perspective After 20 Years of Study
Shevach, E. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01048 · Cited by 150
Wood, L. M., & Paterson, Y. (2014) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2014.00051 · Cited by 157
“Tregs in the tumor microenvironment produce anti-inflammatory cytokines such as IL-10 and TGF-β that impair T cell responses and directly inhibit the function of APCs through interaction with the inhibitory receptor, CTLA-4 (Wing et al., 2008).”
BackgroundImmunobiology of Atherosclerosis: A Complex Net of Interactions
Herrero‐Fernández, B., Gómez-Bris, R., Somovilla-Crespo, B., & González, J. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215293 · Cited by 168
Sjögren's syndrome: Old and new therapeutic targets
Mavragani, C. P., & Moutsopoulos, H. Μ. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102364 · Cited by 167
Phenotypical characterization of regulatory T cells in humans and rodents
Rodríguez-Perea, A. L., Arcia, E. D., Rueda, C. M., & Velilla, P. A. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12804 · Cited by 166
Regulatory T cells in many flavors control asthma
Ray, A., Khare, A., Krishnamoorthy, N., Qi, Z., & Ray, P. (2010) · Mucosal Immunology · doi:10.1038/mi.2010.4 · Cited by 166
Zhang, B., Chikuma, S., Hori, S., Fagarasan, S., & Honjo, T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608873113 · Cited by 166
“Moreover, deletion of CTLA-4 specifically on FoxP3 T cells results in autoimmunity and early death of mice (3).”
BackgroundInfluentialDC subsets in positive and negative regulation of immunity
Coquerelle, C., & Moser, M. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00887.x · Cited by 165
“Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4.”
BackgroundInfluentialHost Immune Response to Infection and Cancer: Unexpected Commonalities
Goldszmid, R. S., Dzutsev, A., & Trinchieri, G. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.003 · Cited by 165
“CTLA4 also scavenges CD80 from the surface of DCs and induces IDO production, mechanisms that may explain how CTLA4-expressing T-reg cells inhibit T cell responses (Fallarino et al., 2005; Wing et al., 2008).”
Juvet, S., & Zhang, L. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjr043 · Cited by 165
“Both of them (i) can play an important role in controlling the development of autoimmune type I diabetes (Green et al., 2003; Ford et al., 2007; Dugas et al., 2010; Duncan et al., 2010), inhibit GVHD (Hoffmann et al., 2002; Young et al., 2003a; our unpublished data), and prevent allograft rejection (Zhang et al., 2000…”
BackgroundInfluentialMultiple treg suppressive modules and their adaptability
Wing, J. B., & Sakaguchi, S. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00178 · Cited by 164
“…primarily www.frontiersin.org June 2012 | Volume 3 | Article 178 | 1 “fimmu-03-00178” — 2012/6/27 — 18:43 — page 2 — #2 via cell extrinsic effects on APCs (Wing et al., 2008) in which Treg expression of CTLA-4 reduces APC expression of CD80 and 86 thus reducing their co-stimulatory capacity…”
BackgroundSelf-citationIpilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
Graziani, G., Tentori, L., & Navarra, P. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2011.09.002 · Cited by 164
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Herzberg, B., Campo, M. J., & Gainor, J. F. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0189 · Cited by 164
Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
Chmiel, K. D., Suan, D., Liddle, C., Nankivell, B., Ibrahim, R., Bautista, C., Thompson, J., Fulcher, D., & Kefford, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2206 · Cited by 164
“Bilirubin umol/L (4-20) Albumin g/L (36-47)”
Jones, A., Bourque, J., Kuehm, L., Opejin, A., Teague, R. M., Gross, C., & Hawiger, D. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.008 · Cited by 154
“Further, specific immunomodulatory mole- cules, such as CTLA-4 and PD-L1, function in tolerance and Treg cell induction by DCs (Fife et al., 2009; Francisco et al., 2009; Probst et al., 2005; Wang et al., 2008; Wing et al., 2008).”
Davis, R. J., Van Waes, C., & Allen, C. T. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.002 · Cited by 163
“Conditional knockout of CTLA4 in Tregs impaired their suppressive function and protected from tumor development [112].”
BackgroundImmune targets in the tumor microenvironment treated by radiotherapy
Ozpiskin, O. M., Zhang, L., & Li, J. J. (2019) · Theranostics · doi:10.7150/thno.32648 · Cited by 163
“During this process, radiation derived DAMPs is required for APCs (antigen-presenting cells) activation and phagocytosis [30].”
BackgroundInfluentialOvcinnikovs, V., Ross, E. M., Petersone, L., Edner, N. M., Heuts, F., Ntavli, E., Kogimtzis, A., Kennedy, A., Wang, C. J., Bennett, C. L., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw0902 · Cited by 157
Zhang, L., Bertucci, A. M., Ramsey-Goldman, R., Burt, R. K., & Datta, S. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901773 · Cited by 162
Hannani, D., Vétizou, M., Enot, D., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaib, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.3 · Cited by 162
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future
Perazella, M. A., & Shirali, A. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018050488 · Cited by 162
Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy
Liu, Y., & Zheng, P. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.11.003 · Cited by 162
The clinical utility of inhibiting CD28‐mediated costimulation
Linsley, P. S., & Nadler, S. G. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00780.x · Cited by 162
“Characterization of T-regulatory cells (Tregs) over the past several years has implicated CD28 and CTLA-4 signals in the generation and activity of this cell type (25).”
BackgroundCHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency
Lo, B., Fritz, J. M., Su, H. C., Uzel, G., Jordan, M. B., & Lenardo, M. J. (2016) · Blood · doi:10.1182/blood-2016-04-712612 · Cited by 155
“In mice with complete germ-line deficiency of CTLA-4, unrestrained T-cell expansion causes death at 4 weeks old,(2,3) whereas the loss of CTLA-4 selectively on Treg cells leads to fatal lymphoproliferation by;7 weeks of age.(28) In CHAI patients, compromising a single allele can predispose them to severe infiltrative…”
BackgroundAutoimmunity and primary immunodeficiency: two sides of the same coin?
Schmidt, R. E., Grimbacher, B., & Witte, T. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.198 · Cited by 164
Anti–CTLA-4 therapy requires an Fc domain for efficacy
Ingram, J. R., Blomberg, O. S., Rashidian, M., Ali, L., Garforth, S., Fedorov, E., Fedorov, A. A., Bonanno, J. B., Le Gall, C., Crowley, S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801524115 · Cited by 150
“H11 bound to CTLA-4 in permeabilized spleen cells, showing preferential staining of CD3CD4CD25 T cells, as has been reported for conventional anti–CTLA-4 antibodies (20, 21).”
BackgroundTargeting T Cell Metabolism for Improvement of Cancer Immunotherapy
Le Bourgeois, T., Strauss, L., Aksoylar, H.-I., Daneshmandi, S., Seth, P., Patsoukis, N., & Boussiotis, V. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00237 · Cited by 152
“Importantly, de novo FAS vs. uptake control the differentiation decision between Th17 and Treg cells (75, 76).”
BackgroundInfluentialYewdall, A. W., Drutman, S. B., Jinwala, F., Bahjat, K. S., & Bhardwaj, N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011144 · Cited by 151
“One significant barrier to therapeutic stimulation of anti-tumor immunity is constituents of the tumor microenvironment [10] such as secreted immunosuppressive factors [11], myeloid-derived suppressor cells [12], and regulatory T cells [13], that adversely affect DC activation and consequently blunt the generation of…”
BackgroundAntitumor Immunity and Cancer Stem Cells
Schatton, T., & Frank, M. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04568.x · Cited by 161
Induction of T cell anergy: integration of environmental cues and infectious tolerance
Chappert, P., & Schwartz, R. H. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.08.005 · Cited by 131
Dynamics of peripheral tolerance and immune regulation mediated by Treg
Sakaguchi, S., Wing, K., & Yamaguchi, T. (2009) · European Journal of Immunology · doi:10.1002/eji.200939688 · Cited by 165
“activated effector T cells expressing CTLA-4 can down-modulate CD80/CD86 expression on DC presumably via CTLA-4 and also frequently secrete IL-10, suggesting that activated effector T cells may concurrently down-modulate APC function in a negative feedback manner via CTLA-4 and IL-10 [ 13 , 45].”
BackgroundSelf-citationRegulatory T-cell therapy in Crohn’s disease: challenges and advances
Clough, J. N., Omer, O. S., Tasker, S., Lord, G. M., & Irving, P. M. (2020) · Gut · doi:10.1136/gutjnl-2019-319850 · Cited by 160
Advances in immunotherapy for melanoma
Redman, J. M., Gibney, G. T., & Atkins, M. B. (2016) · BMC Medicine · doi:10.1186/s12916-016-0571-0 · Cited by 160
“evidence suggests that expression of CTLA-4 on Tregs is important in T cell inhibition [12].”
BackgroundRegulatory T cells, inflammation and the allergic response—The role of glucocorticoids and Vitamin D
Dimeloe, S., Nanzer, A., Ryanna, K., & Hawrylowicz, C. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.02.029 · Cited by 160
Follicular regulatory T cells control humoral autoimmunity via NFAT2-regulated CXCR5 expression
Vaeth, M., Müller, G., Stauss, D., Dietz, L., Klein-Hessling, S., Serfling, E., Lipp, M., Berberich, I., & Berberich-Siebelt, F. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130604 · Cited by 160
Surveillance of Antigen-Presenting Cells by CD4+CD25+ Regulatory T Cells in Autoimmunity
André, S., Tough, D. F., Lacroix‐Desmazes, S., Kaveri, S. V., & Bayry, J. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080987 · Cited by 161
“These data thus indicate that CTLA-4 engagement of B7 molecules on DCs represents a critical mechanism of tolerance induction in vivo.(15,30) Treg-derived IL-10 and TGF- confer a suppressive phenotype on human Mo-DCs, circulating myeloid DCs, and murine BM-DCs and inhibit expression of inflammatory cytokines in vitro.”
BackgroundInfluentialCTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells
Herrmann, A., Priceman, S. J., Kujawski, M., Xin, H., Cherryholmes, G. A., Zhang, W., Zhang, C., Lahtz, C., Kowolik, C. M., Forman, S. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73174 · Cited by 160
“Although CD8+ T cells are known to express low levels of CTLA4, the biological functions of CTLA4 have mainly been characterized in CD4+ Tregs and Th cells (24, 26, 35).”
The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer
Pastille, E., Wasmer, M.-H., Adamczyk, A., Vu, V. P., Mager, L. F., Phuong, N. N. T., Palmieri, V., Simillion, C., Hansen, W., Kasper, S., et al. (2019) · Mucosal Immunology · doi:10.1038/s41385-019-0176-y · Cited by 150
Robb, R. J., Lineburg, K. E., Kuns, R. D., Wilson, Y. A., Raffelt, N. C., Olver, S. D., Varelias, A., Alexander, K. A., Teal, B. E., Sparwasser, T. D., et al. (2012) · Blood · doi:10.1182/blood-2011-12-396119 · Cited by 161
CD4 + CD25 + regulatory T cells in tumor immunity
Chen, X., Du, Y., Lin, X., Qian, Y., Zhou, T., & Huang, Z. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.03.009 · Cited by 163
Toor, S. M., Murshed, K., Al-Dhaheri, M., Khawar, M., Abu Nada, M., & Elkord, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02936 · Cited by 158
“CTLA-4 is constitutively expressed on Tregs and modulates their functionality (57).”
BackgroundChemokines and cancer: new immune checkpoints for cancer therapy
Karin, N. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.004 · Cited by 158
Regulatory T cells in the tumour microenvironment
Imianowski, C. J., Chen, Q., Workman, C. J., & Vignali, D. A. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00832-9 · Cited by 162
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03912.x · Cited by 141
Drug discovery in advanced prostate cancer: translating biology into therapy
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 160
T cell dysfunction and therapeutic intervention in cancer
Zebley, C. C., Zehn, D., Gottschalk, S. M., & Chi, H. (2024) · Nature Immunology · doi:10.1038/s41590-024-01896-9 · Cited by 159
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy
Kim, J.-H., Kim, B. S., & Lee, S. (2020) · Immune Network · doi:10.4110/in.2020.20.e4 · Cited by 158
“The majority of observations seem to indicate that, CTLA-4-dependent and/or highaffinity IL-2R-dependent suppression of T cell activity is an especially crucial process for immunosuppression by Tregs: mice specifically lacking CTLA-4 in Tregs have impaired Tregmediated immunosuppression (43); heterozygous CTLA4 mutati…”
Background
Metadata
- Authors
- Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S.
- Affiliations
- Tohoku University (JP)
- Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
- Corresponding author
- Wing, Kajsa
- Sakaguchi, Shimon
- Venue
- Science
- Published
- 2008-10-10
- Volume
- 322
- Issue
- 5899
- Pages
- 271-275
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2061071534
- Cited by
- 2,956
- References
- 25
- Citations by year
- 2026: 122 · 2025: 129 · 2024: 154 · 2023: 142 · 2022: 162 · 2021: 198 · 2020: 186 · 2019: 205 · 2018: 197 · 2017: 187 · 2016: 174 · 2015: 162 · 2014: 158 · 2013: 170 · 2012: 167
- FWCI
- 61.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4, Foxp3+ regulatory T cells, Treg suppressive function, lymphoproliferation, autoimmune disease, immunoglobulin E, antitumor immunity, dendritic cells, CD80, CD86, antigen presentation, immune tolerance
- MeSH terms
- Animals, Antigen-Presenting Cells, Autoimmune Diseases, Dendritic Cells, Female, Immunoglobulin E, Immunoglobulin G, Immune Tolerance, Leukemia, Lymphocyte Activation, Lymphocytes, Male, Mice, Inbred BALB C, Down-Regulation, Autoimmunity, Antigens, CD, B7-1 Antigen, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, B7-2 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.